Condition: Migraine · Episodic Migraine · Chronic Migraine, Headache · Sponsor: Hospital Universitari Vall d'Hebron Research Institute
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
This description comes directly from the study's public registry record.
Patricia Pozo-Rosich, MD, PhD · (+34) 93 489 30 00 · cefalea@vhir.org
Edoardo Caronna, MD, PhD · (+34) 93 489 30 00 · cefalea@vhir.org
Always discuss trial participation with your own doctor first.
| University of Miami, Miller School of Medicine | Miami, Florida, United States | Recruiting |
| FLENI | Buenos Aires, Argentina | Recruiting |
| Pontificia Universidad Católica de Chile | Santiago, Chile | Recruiting |
| Neuromedica | Medellín, Colombia | Recruiting |
| Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno | Rovinj, Croatia | Recruiting |
| Charité Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
| LMU University Hospital | München, Germany | Recruiting |
| University of L'Aquila | L’Aquila, Italy | Recruiting |
| University of Modena and Reggio Emilia | Modena, Italy | Recruiting |
| National Neurological Institute C. Mondino Foundation | Pavia, Italy | Recruiting |
| IRCCS San Raffaele | Roma, Italy | Recruiting |
| Universiti Putra Malaysia | Serdang, Selangor, Malaysia | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07159750